Kala Pharma shares fall on mixed results from dry eye drug trials

(Reuters) - Shares of Kala Pharmaceuticals Inc slumped over 15 percent before the bell on Friday as the company reported mixed results from two late-stage studies testing its drug to provide temporary relief from dry eye disease.